Article Sidebar

Submitted
11 January 2021
Accepted
11 January 2021
Published
30 September 2020
Download
PDF
Statistic
Read Counter : 564 Download : 707

Main Article Content

Abstract

Acute ischemic stroke is the leading cause of death and causing permanent disability in adults worldwide. In acute ischemic stroke, IL-6 levels positively correlated to more severe neurological deficits, more extensive brain damage and worse prognoses. The use of statin was associated with milder initial stroke severity, better functional outcome and lower mortality. This clinically randomized controlled trial study was aimed to analyze the serum levels of IL 6 in acute ischemic stroke patients who treated with Simvastatin 20 mg compare to placebo. Samples were taken using consecutive sampling method from hospitalized acute ischemic stroke patients in Neurology Department of Dr. Soetomo Teaching Hospital Surabaya and Airlangga University Hospital Surabayafrom August to November 2017. Total of 44 patients met the inclusion criteria, consisting of 22 patients in treatment group and 22 patients in control group.There were no significant difference in the characteristic of the patients in both groups (p>0.05). Averages of serum IL-6 in the control and the treatment group are 38.594±74.313 and 17.760±25.253(p=0,438) while averages of serum IL-6 post in the control group and the treatment are 46.586±103.484 and 15.275±17.183 (p=0,589). There were no significant level escalation in pre and post of control group (p = 0.205) and also no significant level reduction in pre and post of treatment group (p = 0.411), while the average difference in the control group (-7.992 + 78.912 pg/ml) and in the treatment group (2.485 + 23.738 pg/ml).

Keywords

Acute ischemic stroke IL-6 Simvastatin

Article Details

License

Copyright (c) 2020 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Meo, M. L., Machin, A., & Hasmono, D. (2020). Effect of Simvastatin in Serum Interleukin-6 Level in Patients with Acute Ischemic Stroke. Folia Medica Indonesiana, 56(3), 165–173. https://doi.org/10.20473/fmi.v56i3.24508
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Abbas, A. K., Lichtman, A. H., & Pillai, S. (2016). Imunologi Dasar Abbas " Fungsi Dan Kelainan Sistem Imun" (Edisi Indonesia kelima ed.). Singapore: Elsevier.
  2. Adibhatla, R. M., & Hatcher, J. (2005). Cytidine 5"²-Diphosphocholine (CDP-Choline) in Stroke and Other CNS Disorders. Neurochem Res, 30(1)(2005), 15-23.
  3. Balitbangkes. (2013). Riset Kesehatan Dasar . Jakarta: Kementrian Kesehatan Republik Indonesia.
  4. Benjamin, E. J., Blaha, M. J., Chiuve, S. E., & Cushman, M. (2017). American Heart Association - Heart Disease and Stroke Statistics. Circulation, 135(2017), 229-268.
  5. Bonaventura, A., & Liberale, L. (2016). Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. International Journal of Molecular Sciences, 1-53.
  6. Bonilla, L., & Campos, M. (2012). Evidence for the Efficacy of Statins in Animal Stroke Models : A Meta Analysis. Journal of Neurochemistry, 122(2012), 233-243.
  7. Cazacu, I., Mogosan, C., & Loghin, F. (2015). Safety Issues of Current Analgesics: An Update. Clujul Medical 2015 Vol. 88 - no. 2, 88(2015), 128-136.
  8. D0l14, D. N., Barr, T. L., & Simpkins, J. W. (2014). Cytokines: Their Role in Stroke and Potential Use as Biomarkers and Therapeutic Targets. Aging and Disease, 5(2014), 294-306.
  9. Deb, P., Sharma, S., & K, H. (2010). Pathophysiologic Mechanisms of Acute Ischemic Stroke: An overview with Emphasis on Therapeutic Significance Beyond Thrombolysis. Elsevier, 197-218.
  10. Fang, J.-x., Er-qiang, F., Wang, W., Liu, Y., & Cheng, G. (2017). The Efficacy and Ssafety of High-Dose Statins in Acute Phase of Ischemic Stroke and Transient Ischemic Attack: a Systematic Review. Springer(2017), 1-9.
  11. Folsom, A. R., Desvarieux, M., Nieto, J. F., & Boland, L. L. (2003). B Vitamin Status and Inflammatory Markers. Atherosclerosis - Elsevier 169 (2003) 169/174, 169(2003), 169-174.
  12. Gesuete, R., Kohama, S. G., & Stenzel-Poore, M. (2014). Toll-Like Receptors and Ischemic Brain Injury. American Association of Neuropathologists, 378-386.
  13. Hariri, M., Maghsoudi, Z., Darvishi, L., Askari, G., & Hajis, M. (2013). B Vitamins and Antioxidants Intake is Negatively Correlated with Risk of Stroke In Iran. International Journal of Preventive Medicine , 4(2013), 284–289.
  14. Hong, K.-S., & Lee, J. S. (2015). Statins in Acute Ischemic Stroke: A Systematic Review. Journal of Stroke, 17(3)(2015), 282-301.
  15. KEMENKES. (2015). Keputusan Menteri Kesehatan Republik Indonesia tentang Formularium Nasional. Jakarta: KEMENTERIAN KESEHATAN REPUBLIK INDONESIA.
  16. Kim, J. Y., & Yenari, M. A. (2013). The Immune Modulating Properties of The Head Shock Proteins after Brain Injury. Anatomy & Cell biology, 46(2012), 1-7.
  17. Malloy M, J., & Kane J, P. (2015). Agent Used in Dyslipidemia. In K. B, M. S, & T. A, Basic & Clinical Pharmacology 13th Edition (pp. 619-634). New York: McGraw-Hill Companies.
  18. Misbach, J., Soertidewi, L., & Jannis, J. (2011). STROKE, Aspek Diagnostik, Patofisiologi, Manajemen. Jakarta: FKUI.
  19. Montaner, J., Chacon, P., & Krupinski, J. (2008). Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. European Journal of Neurology, 15, 82-90.
  20. Mozaffarian, D., Benyamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., . . . Jimenez, M. C. (2016). Herat Disease And Stroke Statistics - 2016 Update, A Report From The American Heart Association Statistics Commitee and Stroke Statistics Subcommitee Circulation. Circulation, 1-323.
  21. Neema, K. (2015). The Science of Ischemic Stroke: Pathophysiology & Pharmacological Treatment. International Journal of Pharma Research & Riview, 65-84.
  22. Rasmussen, L. M., Hansen, P. R., Nabipour, M. T., & Olesen, P. (2001). Deverse Effects of Inhibition of 3-hydroxy-3-methylglutaryl-CoA Reductase on The Expression of VCAM-1 and E-selectin in Endothelial Cells. Biochemical Journal, 363-370.
  23. Samai, A. A., & Martin-Schild, S. (2015). Sex Differences in Predictors of Ischemic Stroke: Current Perspectives . Dove Press Journal, 11(2015), 427-436.
  24. Shenhar-Tsarfaty, S., Assayag, B. E., I, B., L, S., M, F., S, B., . . . N, B. (2010). Interleukin-6 as an Early Predictor for One-year Survival Following an Ischaemic Stroke/Transient Ischaemic Attack. World Stroke Organization International Journal of Stroke, 5(2010), 16-20.
  25. Smith, C. J., Hedley, C., & Hedley. (2004). Peak Plasma Interleukin-6 and Other Peripheral Markers of Inflammation In The First Week of Ischaemic Stroke Correlate with Brain Infarct Volume, Stroke Severity and Long-Term Outcome. BMC Neurology, 4:2(2004), 1-8.
  26. Smith, W. S., English, J. D., & Johnston, C. S. (2013). Cerebrovascular Diseases. In D. L. Longo, D. L. Kasper, L. J. Jameson, A. S. Fauci, S. L. Hauser, & J. Loscalzo, HARRISON'S Neurology In Clinical Medicine, 3rd Edition (pp. 256-273). New York: McGraw-Hill Education.
  27. Suharjono. (2017). Orasi Ilmiah " Kajian Polifarmasi dari Aspek Interaksi, Efektifitas dan Keamanan Obat". Surabaya: Airlangga University Press.
  28. Syaafi, S., Sharifipour, E., & S, A. (2014). Interleukin-6, a reliable prognostic factor for ischemic stroke. Iranian Journal of Neurology, 70-76.
  29. Tarkowski, E., Rosengren, L., Blomstrand, C., Wikkelso, C., Jensen, C., Ekholm, S., & Tarkowski, A. (1995). Early Intrathecal Production of Interleukin-6 Predicts the Size of Brain Lesion in Stroke. Stroke, 26, 1393-1398.
  30. Tuttolomondo, A., Domenico, D. R., Rosaria, P., Carlo, M., Valentina, A., Vittoriano, D., & Irene, S. (2016). Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke A Randomized Trial. Medicine, 95(13), 3-11.
  31. Waj05-Andreassen, Krakenes, J., Ulvestad, U., Thomassen, L., Myhr, K., Aarseth, J., & Vedeler, C. A. (2005). IL-6: An Early Marker For Outcome In Acute Ischemic Stroke. Acta Neurologica Scandinavica, 360-365.
  32. Whiteley, e. a. (2009). Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6. PLoS Medicine, 1-12.
  33. Zhao, H., T, J., Eguchi, Wang, & Linkermann. (2015). Role of necroptosis in the pathogenesis of solid organ injury. Nature Publishing Group, 1-10.
  34. Zhao, J. J., Zhang, X., Dong, L., & Wen, Y. (2014). The Many Roles of Statins in Ischemic Stroke. Current Neuropharmacology, 564-574.

Most read articles by the same author(s)

1 2 > >>